CENTRALIZED PURCHASING IN HEALTH
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v7i4.97 |
Resumo: | The centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service. |
id |
RCAP_9688b4e8a0eac1f75b10893b50fb1674 |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/97 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
CENTRALIZED PURCHASING IN HEALTHCOMPRAS CENTRALIZADAS NA SAÚDEThe centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service.A centralização das compras tem vindo a ser cada vez mais uma tendência estratégica, nomeadamente no setor da saúde. Em Portugal, a SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., foi constituída em 2010 como uma central de compras para o setor da saúde. As compras centralizadas podem trazer vantagens, como o aumento da eficiência do processo de compras, mas também desvantagens, como a possibilidade de oligopólio por parte dos fornecedores, gerada pela concorrência imperfeita, e uma resposta mais demorada às unidades mais descentralizadas.Este tema foi objeto de uma reunião de reflexão, que teve como principal objetivo promover um debate sobre aspetos do enquadramento nacional deste processo, desafios da sua implementação, no que respeita aos medicamentos hospitalares, e sugestões de melhoria deste processo.As principais ideias geradas para o sucesso das compras centralizadas indicam que a central de compras deve ser facilitadora e dinâmica e garantir a equidade, segurança, acessibilidade e qualidade dos medicamentos. Deve existir um melhor planeamento e rigor na aquisição dos medicamentos e deve ser criado um sistema de informação integrado que permita a partilha e a comunicação em rede entre a central de compras e as diversas instituições de saúde, fomentando uma política de proximidade. Os profissionais devem ser formados nos procedimentos técnicos necessários para a realização da aquisição dos medicamentos e os farmacêuticos hospitalares devem ser incluídos como consultores no desenvolvimento de alguns procedimentos de aquisição centralizada, em função das necessidades das unidades hospitalares.Por fim, todo este processo deve ser acompanhado de uma constante monitorização, através de uma avaliação anual sobre a racionalidade económico-financeira e vantagens da atividade desenvolvida na perspetiva dos ganhos de qualidade e eficiência, devidamente quantificados e que demonstrem o impacto financeiro alcançado no âmbito da redução da despesa no Serviço Nacional de Saúde.Formifarma2016-03-12info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v7i4.97https://doi.org/10.25756/rpf.v7i4.97Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 7 No 4 (2015): Outubro; 214-220Revista Portuguesa de Farmacoterapia; v. 7 n. 4 (2015): Outubro; 214-2202183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/97http://revista.farmacoterapia.pt/index.php/rpf/article/view/97/82Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessAperta, JorgeBorges, AndreaCadilha, DianaDimas, FranciscaDinis, CristinaFeio, JoséFonseca, OlímpiaGarcia, MartinhaMarques, FilomenaRibeiro, JoãoRodrigues, CelinaSantos, CláudiaTeixeira, CarmoDimitrovová, Klara2023-09-01T04:33:29Zoai:ojs.farmacoterapia.pt:article/97Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:33.930229Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
CENTRALIZED PURCHASING IN HEALTH COMPRAS CENTRALIZADAS NA SAÚDE |
title |
CENTRALIZED PURCHASING IN HEALTH |
spellingShingle |
CENTRALIZED PURCHASING IN HEALTH Aperta, Jorge |
title_short |
CENTRALIZED PURCHASING IN HEALTH |
title_full |
CENTRALIZED PURCHASING IN HEALTH |
title_fullStr |
CENTRALIZED PURCHASING IN HEALTH |
title_full_unstemmed |
CENTRALIZED PURCHASING IN HEALTH |
title_sort |
CENTRALIZED PURCHASING IN HEALTH |
author |
Aperta, Jorge |
author_facet |
Aperta, Jorge Borges, Andrea Cadilha, Diana Dimas, Francisca Dinis, Cristina Feio, José Fonseca, Olímpia Garcia, Martinha Marques, Filomena Ribeiro, João Rodrigues, Celina Santos, Cláudia Teixeira, Carmo Dimitrovová, Klara |
author_role |
author |
author2 |
Borges, Andrea Cadilha, Diana Dimas, Francisca Dinis, Cristina Feio, José Fonseca, Olímpia Garcia, Martinha Marques, Filomena Ribeiro, João Rodrigues, Celina Santos, Cláudia Teixeira, Carmo Dimitrovová, Klara |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Aperta, Jorge Borges, Andrea Cadilha, Diana Dimas, Francisca Dinis, Cristina Feio, José Fonseca, Olímpia Garcia, Martinha Marques, Filomena Ribeiro, João Rodrigues, Celina Santos, Cláudia Teixeira, Carmo Dimitrovová, Klara |
description |
The centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-03-12 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v7i4.97 https://doi.org/10.25756/rpf.v7i4.97 |
url |
https://doi.org/10.25756/rpf.v7i4.97 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/97 http://revista.farmacoterapia.pt/index.php/rpf/article/view/97/82 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 7 No 4 (2015): Outubro; 214-220 Revista Portuguesa de Farmacoterapia; v. 7 n. 4 (2015): Outubro; 214-220 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129986160918528 |